Mn Services Vermogensbeheer B.V. Sells 6,700 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mn Services Vermogensbeheer B.V. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,960 shares of the medical equipment provider's stock after selling 6,700 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Hologic were worth $5,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in Hologic during the 4th quarter worth approximately $133,414,000. Boston Partners raised its stake in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Champlain Investment Partners LLC purchased a new position in shares of Hologic in the fourth quarter worth $79,291,000. Northern Trust Corp increased its position in Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after acquiring an additional 668,086 shares during the last quarter. Finally, Invesco Ltd. increased its position in Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock valued at $293,434,000 after acquiring an additional 572,187 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is owned by company insiders.

Hologic Trading Up 0.8%

NASDAQ:HOLX traded up $0.51 during mid-day trading on Friday, reaching $64.48. The company's stock had a trading volume of 5,564,249 shares, compared to its average volume of 2,349,728. The company's fifty day simple moving average is $59.29 and its two-hundred day simple moving average is $64.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The stock has a market cap of $14.37 billion, a P/E ratio of 27.21, a P/E/G ratio of 2.36 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the business posted $1.03 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on HOLX shares. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Morgan Stanley dropped their price target on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Evercore ISI dropped their price target on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Argus lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of "Hold" and an average target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.